An Open-label, Multi-center Phase IB/II Study of Abemaciclib With Paclitaxel for CDK4/6 Pathway Activated Tumors
Latest Information Update: 09 Oct 2023
At a glance
- Drugs Abemaciclib (Primary) ; Paclitaxel (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 04 Oct 2023 Planned number of patients changed from 36 to 30.
- 04 Oct 2023 Planned End Date changed from 10 Aug 2022 to 10 Aug 2024.
- 04 Oct 2023 Planned primary completion date changed from 10 Aug 2022 to 10 Aug 2024.